Biodesix Inc (OQ:BDSX)

Business Focus: Medical & Diagnostic Laboratories

Nov 21, 2022 04:01 pm ET
Biodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the closing of its underwritten public offering of 35,075,000 shares of its common stock at a price to the public of $1.15 per share, including the exercise in full by the underwriter of its option to purchase up to an additio
Nov 17, 2022 12:26 am ET
Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the pricing of an underwritten public offering of 30,500,000 shares of its common stock at a price to the public of $1.15 per share, before underwriting discounts and commissions. The gross proceeds to Biodesix from the offeri
Nov 16, 2022 04:05 pm ET
Biodesix Announces Proposed Public Offering of Common Stock
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it has commenced an underwritten public offering of $30 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. In connection with the offering, Biodesix
Nov 16, 2022 04:01 pm ET
Biodesix Announces Senior Secured Financing Agreement with Perceptive Advisors for Up to $50 Million
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it has obtained a term loan facility for up to $50 million from Perceptive Advisors, a leading healthcare investment firm focused on supporting progress in the life sciences industry by identifying opportunities and direc
Nov 10, 2022 09:00 am ET
Biodesix Presents New Data from the INSIGHT Study at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Wallace Akerley, MD, medical oncologist at the University of Utah Huntsman Cancer Institute, will present new interim data from the large multi-center prospective observational registry study INSIGHT (Clinical Effectiveness
Nov 03, 2022 06:00 am ET
Biodesix Announces Third Quarter 2022 Results and Highlights
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for third quarter ended September 30, 2022 and provided a corporate update.
Oct 20, 2022 06:00 am ET
Biodesix to Report Third Quarter 2022 Financial Results on November 3, 2022
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, today announced that it will release financial results for the third quarter ended September 30, 2022 before the open of trading on Thursday, November 3. Biodesix’s management will host a conference call and webcast to discuss its financia
Oct 17, 2022 06:00 am ET
Biodesix Awarded U.S. Federal Supply Schedule Contract for Its Comprehensive Lung Cancer Diagnostic Testing Solutions
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the award of a U.S. Federal Supply Schedule contract which includes the Veterans Health Administration providing care for U.S. Veterans and Military Health System providing care for active-duty service members and their famili
Oct 12, 2022 06:00 am ET
Biodesix to Present Data at the CHEST 2022 Annual Meeting Demonstrating High Sensitivity of the Nodify XL2® Blood-Based Lung Nodule Test in Various Patient Populations, Including Individuals Participa
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that three data presentations will occur at the CHEST 2022 Annual Meeting which will be held live and in-person for the first time since 2019. Presentations will include a sub-group analysis of data from the post-market, prospective, real-world ORACLE study (An Observational Registry Study to Evaluate the Performance of the Nodify XL2® Test - ORACLE [NCT03766958]) demonstrating that the Nodify XL2 test has equivalent performance in identifying patients with benign nod
Oct 11, 2022 06:00 am ET
 Biodesix Announces Preliminary Revenue for Third Quarter 2022
Biodesix, Inc. (NASDAQ: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the Company expects to report third quarter 2022 total revenue to be in the range of $10.6 million to $11.2 million, representing growth of 62% to 71% over the third quarter 2021. The strength in the third quarter 2022 total revenue reflects continued growth in the Company’s core lung diagnostic testing. The financial results included in this release pertaining to the third quarter 2022 are preliminary, subject to completion of internal procedures and review.
Sep 06, 2022 06:00 am ET
Biodesix to Participate in Two Upcoming Investor Conferences in September
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences:
Aug 09, 2022 06:00 am ET
Biodesix Named a Top 100 Healthcare Technology Company of 2022
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced it has been recognized in the
Aug 04, 2022 06:00 am ET
Biodesix Announces Second Quarter 2022 Results and Highlights
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for second quarter ended June 30, 2022 and provided a corporate update.
Aug 03, 2022 06:00 am ET
Biodesix to Present at the Canaccord Genuity 42nd Annual Growth Conference
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the Canaccord Genuity 42nd Annual Growth Conference being held August 8-11, 2022.
Jul 20, 2022 06:00 am ET
Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Tr
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Young Kwang Chae, MD, MPH, MBA, Associate Professor of Medicine (Hematology and Oncology) Feinberg School of Medicine, Northwestern University will present the results of a retrospective analysis at the IASLC 2022 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC2022) on August 8, 2022 in Vienna, Austria.
Jul 19, 2022 06:00 am ET
Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, today announced that it will release financial results for the second quarter ended June 30, 2022 before the open of trading on Thursday, August 4. Biodesix’s management will host a conference call and webcast to discuss its financial resu
Jun 07, 2022 06:00 am ET
Biodesix Obtains Medicare Coverage for the Nodify CDT® Lung Nodule Test
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced that WPS Government Health Administrators, the Medicare Administrative Contractor with jurisdiction for Biodesix’s De Soto, Kansas laboratory, has provided coverage for the Nodify CDT® lung nodule test.
Jun 03, 2022 06:00 am ET
Biodesix Announces Research Agreement with Top US Cancer Center
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it intends to develop a new novel minimal residual disease (MRD) test as a part of a master sponsored research agreement (MSRA) with Memorial Sloan Kettering Cancer Center (MSK). In addition, the MSRA between MSK and Biodesix also includes the potential future development of other diagnostic tests aimed at improving the treatment of cancer.
Jun 01, 2022 06:00 am ET
Biodesix to Present at the 42nd Annual William Blair Growth Stock Conference
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the 42nd Annual William Blair Growth Stock Conference being held June 6-9, 2022 at the Lowes Chicago Hotel in Chicago, IL.
May 17, 2022 06:00 am ET
Biodesix to Present at the H.C. Wainwright Global Investment Conference
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present virtually at the H.C. Wainwright Global Investment Conference being held May 23-25, 2022.
May 12, 2022 06:00 am ET
Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to be Presented at ATS 2022 International Conference
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical management decisions in patients with lung nodules will be presented at the American Thoracic Society (ATS) 2022 International Conference. The meeting will take place May 13-18, 2022, in San Francisco, California.
May 11, 2022 06:00 am ET
Biodesix Announces First Quarter 2022 Results and Highlights
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for first quarter ended March 31, 2022 and provided a corporate update.
Apr 27, 2022 06:00 am ET
Biodesix to Report First Quarter 2022 Financial Results on May 11, 2022
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the first quarter ended March 31, 2022 before the open of trading on Wednesday, May 11. Biodesix’s management will host a conference call and webcast to discuss its financial resul
Apr 12, 2022 08:58 am ET
BioMed Stocks On the Move: Nova Mentis, PolarityTE, Biodesix and PharmaDrug; Life Sciences Leaders Report Latest Advances in Regenerative Tissue Technology, New Drugs for Cancers, Glaucoma, and Autism
Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: PolarityTE, Inc. (NASDAQ: PTE) Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Biodesix, Inc. (NASDAQ:...
Apr 12, 2022 08:30 am ET
Thinking about buying stock in Actinium Pharmaceuticals, BioCardia, Veru, Biodesix, or Aeglea Bio Therapeutics?
NEW YORK, April 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATNM, BCDA, VERU, BDSX, and AGLE.
Apr 11, 2022 06:00 am ET
Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term Loan
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the sale of 6,508,376 common shares on April 7, 2022 in a private placement offering that raised approximately $11.7 million in net proceeds to, among other things, fund the partial repayment of its existing term loan and general corpora
Mar 29, 2022 06:00 am ET
Biodesix Announces Publication Further Validating the Use of Liquid Biopsies and NGS Techniques to Provide Clinical Information for Patients With Cancer
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that new data were published in the peer-reviewed journal, Diagnostics (Basel), in an article titled, “Analytic and Clinical Validation of a Pan-Cancer NGS Liquid Biopsy Test for the Detection of Copy Number Amplifications, Fusions and Exon Skipping Variants.” This peer-reviewed publication further validates the GeneStrat NGS test and the use of multiple classes of tumor markers in circulating free nucleic acid analysis as a surrogate for tumor tissue biopsies. i
Mar 14, 2022 06:00 am ET
Biodesix Announces Fourth Quarter and Year End 2021 Results and Highlights
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the fourth quarter and year ended December 31, 2021 (fiscal 2021) and provided a corporate update.
Mar 07, 2022 04:01 pm ET
Biodesix Announces Common Stock Purchase Agreement for up to $50 Million with Lincoln Park Capital
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced it has entered into a purchase agreement for the issuance and sale of its common stock, from time to time, of up to $50 million with Lincoln Park Capital Fund, LLC (LPC), a Chicago-based institutional investor.
Mar 03, 2022 06:00 am ET
Biodesix Announces Impactful Clinical Data on the Primary Immune Response (PIR) Test at the IASLC 2022 Therapies of Lung Cancer Meeting
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced impactful data on the Primary Immune Response (PIR) test at the IASLC 2022 Targeted Therapies of Lung Cancer Meeting. In this body of work, the PIR test provided two classifications of PIR-Not Resistant and PIR-Resistant predictive of likely response to immune checkpoint inhibitors (ICIs). The data showed that the Biodesix PIR test was predictive for survival outcomes when tested at baseline (HR=2.36, p=0.02) or 3 weeks after ICI treatment initiation (HR=3.53, p=0.001
Mar 01, 2022 06:00 am ET
Biodesix to Present at Cowen’s 42nd Annual Healthcare Conference
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at Cowen’s 42nd Annual Healthcare Conference being held virtually March 7-9, 2022.
Feb 28, 2022 06:00 am ET
Biodesix to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, 2022
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the fourth quarter and year ended December 31, 2021 before the open of trading on Monday, March 14. Biodesix’s management will host a conference call and webcast to discuss its fin
Feb 22, 2022 06:00 am ET
Biodesix CEO Scott Hutton Named to The Healthcare Technology Report’s List of Top 25 Biotech CEOs in 2022
Biodesix, Inc. (NASDAQ: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that its Chief Executive Officer was named in The Healthcare Technology Report’s list of Top 25 Biotech CEOs of 2022. The annual list recognizes the most accomplished executives in the biotech industry.
Feb 14, 2022 06:00 am ET
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue (Unaudited)
Biodesix, Inc. (NASDAQ: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the Company expects to report fourth quarter and record full-year 2021 preliminary unaudited total revenue of $7.2 million and $54.5 million, respectively. The strength in the full-year 2021 total revenue of $54.5 million compared to $45.6 million in 2020 was a result of growth in the Company’s core lung diagnostic testing and first half 2021 COVID-19 testing. The financial results included in this release pertaining to the fourth quarter and year ended December 3
Feb 09, 2022 06:00 am ET
Biodesix to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held virtually February 15-17, 2022.
Jan 19, 2022 09:15 am ET
PierianDx and Biodesix Partner to Advance Lung Cancer Diagnostics
PierianDx, the global leader in clinical genomics knowledge, today announced that it has partnered with Biodesix to provide its interpretation technology platform for use with the Biodesix newly launched GeneStrat NGS™ genomic test, a blood-based tumor profiling test to detect actionable mutations in patients with non-small cell lung cancer (NSCLC). Biodesix (N
Jan 18, 2022 06:00 am ET
Biodesix Announces the Launch of its GeneStrat NGS™ Test and the IQLung™ Testing Strategy with Unprecedented Time to Results
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today the national launch of its new GeneStrat NGS™ genomic test, a blood-based tumor profiling test. The 52-gene panel includes guideline recommended mutations to help physicians treating advanced- stage lung cancer patients identif
Jan 04, 2022 04:01 pm ET
Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term Loan
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the sale of 3,756,994 common shares on December 30, 2021 in an at-the-market offering that raised approximately $16.3 million in gross proceeds to fund repayment of its existing term loan.
Dec 08, 2021 06:00 am ET
Biodesix Announces Appointment of Successful Innovator and Scientific Professional Jon Faiz Kayyem, PhD to Board of Directors
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the appointment of Dr. Jon Faiz Kayyem to the company’s board of directors. Dr. Kayyem’s diverse career spans more than 20 years and includes experience in academia, lean startups, and Fortune 100 companies. He has served in various l
Dec 01, 2021 06:00 am ET
Biodesix Partners with Spesana to Streamline Digital Access to Molecular Diagnostics for Precision Medicine in Lung Cancer
Spesana, the developer of a novel electronic operating system to unify EMRs, and
Nov 18, 2021 06:00 am ET
Biodesix Announces Publication Highlighting Interim Data from the INSIGHT Study Assessing the Clinical Effectiveness of VeriStrat® Proteomic Test in the Journal of Immunotherapy of Cancer
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced new interim data published from the large multi-center observational registry study INSIGHT (Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects) (NCT03289780) utilizing its
Nov 15, 2021 07:45 am ET
Biodesix Announces Third Quarter 2021 Results and Highlights
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the third quarter ended September 30, 2021 and provided a corporate update.
Nov 12, 2021 07:00 am ET
Biodesix to Present Data Supporting Proteomic-Based Immunotherapy Diagnostic Tests and AI Explainability in Diagnostic Tests at Society for Immunotherapy of Cancer Annual Meeting
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the company will co-present with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), three posters at the 36th Annual Society for Immunotherapy of Cancer (SITC) Nov. 10 – 14, 2021 from research into diagnostic tests of treatment response of NSCLC patients to immune checkpoint inhibitor therapy.
Nov 11, 2021 06:00 am ET
Biodesix to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum being held virtually November 18, 2021.
Nov 01, 2021 06:00 am ET
Biodesix to Report Third Quarter 2021 Financial Results on November 15, 2021
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the third quarter ended September 30, 2021 before the open of trading on Monday, November 15. Biodesix’s management will host a conference call and webcast to discuss its financial
Oct 13, 2021 06:00 am ET
Biodesix Announces New Data on Nodify Lung® Nodule Risk Assessment Testing at the CHEST 2021 Annual Meeting
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced that multiple data presentations will occur at the 2021 annual CHEST virtual conference. Presentations will include newly emerging data from the post-market, prospective, real-world ORACLE study (An Observational Registry Study to Evaluate the Performance of the Nodify XL2® Test - ORACLE [NCT03766958]), demonstrating that incorporation of this blood-based test in the management of patients with newly detected lung nodules modified physician behavior. The prospectively col
Sep 16, 2021 09:20 am ET
Biodesix Announces Abstracts Presented During the IASLC 2021 World Conference on Lung Cancer
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that two abstracts highlighting proteomic and genomic data based on their diagnostic tests were presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC).
Sep 02, 2021 06:00 am ET
Biodesix to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat the Morgan Stanley Virtual 19th Annual Global Healthcare Conference being held virtually September 9-10 and September 13-15, 2021.
Aug 25, 2021 06:00 am ET
Biodesix DeSoto Laboratory Receives both ISO 13485:2016 Certification and Accreditation from the College of American Pathologists
Biodesix, Inc. (Nasdaq: BDSX). Today Biodesix announced that the Accreditation Committee of the College of American Pathologists (CAP) and British Standards Institute (BSI) on behalf of International Organization for Standardization (ISO) recently awarded both CAP accreditation and ISO 13485:2016 certification to the Biodesix Laboratory located in D
Aug 10, 2021 04:01 pm ET
Biodesix Announces Second Quarter 2021 Results and Highlights
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the second quarter ended June 30, 2021 and provided a corporate update.
Aug 02, 2021 06:00 am ET
Biodesix to Present at the Canaccord Genuity 41st Annual Growth Conference
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the Canaccord Genuity 41st Annual Growth Conference being held virtually August 10-12, 2021.
Jul 27, 2021 06:00 am ET
Biodesix to Report Second Quarter 2021 Financial Results on August 10, 2021
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the second quarter ended June 30, 2021 after the close of trading on Tuesday, August 10. Biodesix’s management will host a conference call and webcast to discuss its financial resu
Jun 17, 2021 04:01 pm ET
Biodesix Announces Presentation on Novel Proteomic Techniques in Partnership with Seer
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced in partnership with Seer, Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, a webinar to present the newest trends in proteomics for biomarker discovery and translational research. The webinar entitl
Jun 15, 2021 06:00 am ET
Biodesix Announces Commercial Availability of SARS CoV-2 Neutralization Antibody Test
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the broad commercial launch of a SARS CoV-2 Neutralization Antibody Test (cPass™ Neutralization Test Kit, GenScript Inc.). The test uses ELISA technology to detect circulating neutralizing antibodies against the receptor bi
Jun 04, 2021 09:00 am ET
Biodesix Partners with Datavant to Enhance Value of Lung Cancer Databank
Biodesix, a leading lung cancer diagnostic solutions company, announced a strategic partnership with Datavant, the leader in helping healthcare organizations safely connect their data. Datavant provides solutions to help protect, match, and share...
Jun 04, 2021 06:00 am ET
Biodesix Partners with Datavant to Enhance Value of Lung Cancer Databank
Biodesix, Inc. (Nasdaq: BDSX), a leading lung cancer diagnostic solutions company, announced a strategic partnership with Datavant, a leader in helping healthcare organizations safely connect their data. Datavant provides solutions to help protect, match, and share health data. Through this partnership, Biodesix will anonymize the lung cancer
May 25, 2021 06:00 am ET
Biodesix to Present at the William Blair 41st Annual Growth Stock Conference
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the William Blair 41st Annual Growth Stock Conference being held virtually June 1-3, 2021.
May 11, 2021 04:01 pm ET
Biodesix Announces First Quarter 2021 Results
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced financial and operating results for the first quarter ended March 31, 2021 and provided a corporate update.
Apr 28, 2021 06:00 am ET
Biodesix Announces Intent to Launch Liquid Biopsy Next Generation Sequencing Test with Unprecedented Turnaround Time
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, has announced their plan to add a blood-based 52-gene next generation sequencing (NGS) test to their portfolio of molecular testing based on a recent publication. Of critical importance, the publication, “
Apr 26, 2021 04:01 pm ET
Biodesix Announces Presentation on SARS-CoV-2 Neutralizing Antibody Testing for Individual Vaccine Response and Commercial Launch Plans
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced in partnership with GenScript Biotech Corporation, a webinar to present novel data on the rapid detection of total SARS-CoV-2 neutralizing antibodies using cPass™ technology. Neutralizing antibodies may specifically block t
Apr 26, 2021 06:00 am ET
Biodesix to Report First Quarter 2021 Financial Results on May 11, 2021
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the first quarter ended March 31, 2021 after the close of trading on Tuesday, May 11. Biodesix’s management will host a conference call and webcast to discuss its financial results
Apr 22, 2021 06:00 am ET
Biodesix Announces Presentation on Use of Biomarker-Based Risk Assessment to Inform Lung Nodule Management
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced a webinar to discuss biomarkers and risk assessment in lung nodule management. The virtual session, hosted by the American College of Chest Physicians® (CHEST) and led by Susan Garwood, MD, National Physician Dir
Apr 10, 2021 08:30 am ET
Biodesix Releases New Data at AACR on Proteomic Profiling to Help Guide Physician Treatment Strategies for NSCLC Patients
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that three abstracts from multiple clinical studies will be showcased at the 2021 American Association for Cancer Research (AACR) Annual Meeting being held virtually April 10-15, 2021 and May 17-21, 2021. Findings from thes
Apr 06, 2021 06:00 am ET
Biodesix Announces Issuance of Two U.S. Patents, Expands Coverage of Diagnostic Methods to Improve Care for Cancer Patients
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the United States Patent and Trademark Office (USPTO) has issued two patents that will enhance its ability to develop blood-based immunotherapy and pipeline testing strategies. These developments further improve Biodes
Mar 23, 2021 04:00 pm ET
Biodesix Announces Closing of New $30 Million Term Loan
Biodesix, Inc. (NASDAQ: BDSX; “Biodesix” or the “Company”) a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that it has closed on a new $30 million term loan (New Term Loan) which matures on March 1, 2026.
Mar 16, 2021 03:00 pm ET
Biodesix Announces Fourth Quarter and Full Year 2020 Results
Biodesix, Inc. (NASDAQ: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced financial and operating results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.
Mar 09, 2021 05:00 am ET
Biodesix to Report Fourth Quarter and Fiscal 2020 Financial Results on March 16, 2021
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the fourth quarter and year ended December 31, 2020 after the close of trading on Tuesday, March 16. Biodesix’s management will host a conference call and webcast to discuss its fi
Feb 25, 2021 06:30 am ET
Biodesix CEO Scott Hutton Selected as One of Top 25 Biotech CEOs of 2021
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that The Healthcare Technology Report announced Chief Executive Officer, Scott Hutton, as one of the
Feb 16, 2021 06:30 am ET
Biodesix Partners with Chicago Public Schools for COVID-19 Testing to Safely Reopen Schools
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the company has partnered with Chicago Public Schools (CPS) to provide antigen and Droplet Digital PCR (ddPCR)™ testing for Chicago Public School teachers and staff. The CPS testing program, which launched in January,
Feb 12, 2021 06:30 am ET
Biodesix to Participate in Two February Conferences
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that management will participate in two upcoming conferences: the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which is being held February 17-19, 2021, and the LifeSci Partners Precisio
Feb 09, 2021 06:30 am ET
Biodesix Publishes Data on New COVID-19 Artificial Intelligence (AI)-Based Algorithm for Use in Clinical Decision Support Systems
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced a publication describing the development of a new AI-based COVID-19 algorithm and the important data from a related study. The paper, entitled, “
Feb 02, 2021 07:30 am ET
Scott Hutton of Biodesix Selected as USA Chief Executive Officer of the Year by CEO Monthly Magazine
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that Chief Executive Officer Scott Hutton was
Jan 26, 2021 06:30 am ET
Biodesix to Showcase New Data on Patient Immune Profiling from Multiple Studies at World Lung Conference
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that three abstracts from multiple clinical studies will be featured at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC), scheduled for January 28-31, 2021. Findings
Jan 13, 2021 07:00 am ET
Jan 13, 2021 06:00 am ET
HiberCell and Biodesix Initiate Broad Collaboration for Companion Diagnostic Discovery, Development and Commercialization
NEW YORK and BOULDER, Colo., Jan. 13, 2021 /PRNewswire/ -- HiberCell, a biotechnology company developing novel therapeutics for cancer relapse and metastasis, today announced an agreement with Biodesix, Inc. (Nasdaq: BDSX) to further the development of an enzyme-linked immunosorbent assay (ELISA) as a companion diagnostic in future registrational trials in breast cancer for Imprime PGG programs. Terms of the partnership were not disclosed.
Jan 08, 2021 06:00 am ET
Biodesix Anticipates Strong Preliminary Fourth Quarter 2020 Revenue (unaudited)
Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the company expects to report record fourth quarter 2020 preliminary unaudited revenue in a range of $25 million to $27 million. The strength in the fourth quarter 2020 was a result of growth in the company’s COVID-19 testing services, lung diagnostic testing, and biopharma services. The financial results included in this release pertaining to all interim periods are unaudited and the financial results as of and for the three-month period ended December 31, 2020 are preliminary
Jan 06, 2021 06:00 am ET
Purdue Partners With Colorado Company to Offer Rapid Testing for Students Ahead of Spring 2021 Semester
Purdue University is partnering with a Colorado company led by a Purdue alum to offer rapid antigen COVID-19 testing for undergraduate, graduate and professional students taking classes on the West Lafayette campus who will be living off campus (not in the residence halls or in Fraternity, Sorority and Cooperative Life housing) during the spring 2021 semester.
Jan 05, 2021 06:00 am ET
Biodesix Announces Hiring of Ryan Siurek as Chief Accounting Officer
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that Ryan Siurek has joined the company as Chief Accounting Officer reporting to Ms. Robin Harper Cowie, Chief Financial Officer.
Dec 23, 2020 06:00 am ET
Biodesix Initiates Biomarker Study to Affirm Nodify XL2® Test’s Importance in Clinical Decision Making
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, is proud to announce the launch and active recruitment of a first-in-class biomarker study aligned with the recommendations from the official 2018 American Thoracic Society (ATS)
Dec 15, 2020 06:00 am ET
Biodesix Study Shows Proprietary Device Collects, Separates, and Transports Blood at Ambient Temperature
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced publication of a peer-reviewed study supporting its patented blood collection device (BCD). The device is designed to streamline whole blood specimen collection and transportation to the laboratory while delivering diagnostic test results that are equiv
Dec 10, 2020 05:24 pm ET
Biodesix Announces Third Quarter 2020 Results and Provides Corporate Update
Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, today announced financial and operating results for the third quarter ended September 30, 2020 and provided a corporate update.
Dec 01, 2020 06:00 am ET
Biodesix Publishes Extended Analyses of the Nodify XL2® Lung Nodule Test
Biodesix, Inc. (Nasdaq: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced publication of an analysis of the company’s Nodify XL2® lung nodule test. The test supports clinical decision-making for suspicious nodules by more accurately identifying patients with a very low risk of malignancy
Oct 30, 2020 04:15 pm ET
Biodesix Announces Closing of Initial Public Offering
Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix”) today announced the closing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $18.00 per share. The gross proceeds to Biodesix, before deducting underwriting discounts and commissions, were approximately $72.0 million. The shares began trading on The Nasdaq Global Market on October 28, 2020, under the symbol “BDSX.”
Oct 28, 2020 05:00 am ET
Biodesix Announces Pricing of Initial Public Offering
Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix”) today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $18.00 per share. The shares are expected to begin trading on The Nasdaq Global Market on October 28, 2020, under the symbol “BDSX.” The offering is expected to close on October 30, 2020, subject to the satisfaction of customary closing conditions. In addition, Biodesix has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock at the initial public offering price, less underw

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.